The Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview
| Journal | Current oncology (Toronto, Ont.) |
| Study Type | Randomized Trial |
| Population | Human participants |
This represents the first systematic national effort to establish clinical infrastructure for psychedelic-assisted therapy in cancer care. The focus on demoralization syndrome addresses a well-documented but undertreated aspect of cancer-related psychological distress that conventional supportive care often fails to adequately manage.
CAN-PACT is a comprehensive multi-phase program launching in 2025 to develop psychedelic-assisted therapy capacity across Canada for cancer patients experiencing demoralization syndrome. The initiative encompasses six objectives from building interdisciplinary networks and clinician training to conducting multi-center randomized controlled trials. While this is a program overview rather than completed research, it establishes the framework for what will become the largest systematic study of psychedelic therapy in oncology supportive care. The program specifically targets advanced cancer patients experiencing loss of meaning, dysphoria, and helplessness – symptoms that cluster as demoralization syndrome and are distinct from traditional depression or anxiety.
“I view this as essential infrastructure development rather than breakthrough science. The clinical need is established – what’s been missing is the systematic approach to training, protocols, and evidence generation that CAN-PACT promises to deliver.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is demoralization syndrome in cancer patients and why does it need specialized treatment?
Demoralization syndrome is a psychological condition characterized by loss of meaning, dysphoria, disheartenment, helplessness, and a sense of failure commonly experienced by cancer patients. CAN-PACT was specifically launched to address this urgent gap in supportive care, as traditional therapies may be insufficient for the existential distress associated with advanced cancer diagnosis.
What is psychedelic-assisted therapy (PAT) and how might it help cancer patients?
Psychedelic-assisted therapy combines psychedelic substances with structured psychological support to address mental health conditions. For cancer patients, PAT shows promise in treating demoralization syndrome and related psychosocial distress that traditional interventions may not adequately address.
What training and safety protocols are being developed for PAT in cancer care?
CAN-PACT’s third objective specifically focuses on developing comprehensive PAT training and education for clinicians, researchers, and patients. The program includes pilot testing of intervention and assessment procedures to ensure safety and feasibility before broader implementation.
What research evidence will CAN-PACT provide for PAT in cancer care?
CAN-PACT plans to conduct a multi-center, randomized controlled trial of PAT for people with advanced cancer, which will provide high-quality evidence for its effectiveness. The program also includes structured stakeholder engagement to set research priorities and ensure clinically relevant outcomes.
How might CAN-PACT influence healthcare policy regarding psychedelic therapy?
One of CAN-PACT’s six major objectives is to inform and influence healthcare policy on PAT in Canada through evidence generation and capacity building. The program aims to create a national interdisciplinary network that can guide policy decisions based on rigorous research and clinical experience.
